| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1028443412 |
| P356 | DOI | 10.1007/S00296-007-0341-6 |
| P698 | PubMed publication ID | 17404733 |
| P50 | author | Karen H Costenbader | Q87706447 |
| Lori B Chibnik | Q91244792 | ||
| Elizabeth W Karlson | Q98839527 | ||
| P2093 | author name string | Matthew H Liang | |
| Victoria Gall | |||
| Hannah Kwon | |||
| Juliet Aizer | |||
| P2860 | cites work | Cardiovascular disease in lupus patients: should all patients be treated with statins and aspirin? | Q28191540 |
| The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 | ||
| Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus | Q29614922 | ||
| Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group | Q29619842 | ||
| Drug treatment of lipid disorders | Q33707765 | ||
| The evolving role of statins in the management of atherosclerosis | Q33818141 | ||
| Current perspectives on statins | Q33818381 | ||
| How to improve morbidity and mortality in systemic lupus erythematosus | Q33902390 | ||
| Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus | Q33974679 | ||
| Premature coronary-artery atherosclerosis in systemic lupus erythematosus | Q33974685 | ||
| Clinically relevant differences between the statins: implications for therapeutic selection | Q34093408 | ||
| Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus | Q34098573 | ||
| Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). | Q34164324 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial | Q34501729 | ||
| A controlled comparison of brachial artery flow mediated dilation (FMD) and digital pulse amplitude tonometry (PAT) in the assessment of endothelial function in systemic lupus erythematosus | Q37369357 | ||
| Measurement of systemic lupus erythematosus activity in clinical research | Q39653459 | ||
| Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. | Q40415334 | ||
| Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury | Q40696585 | ||
| Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences | Q41478162 | ||
| Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus | Q41608189 | ||
| Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population | Q42037849 | ||
| Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). | Q43812097 | ||
| Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project | Q43855163 | ||
| Antiinflammatory effect of simvastatin in patients with rheumatoid arthritis | Q44137425 | ||
| Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression | Q44746783 | ||
| Effect of pravastatin on outcomes after cardiac transplantation. | Q46203599 | ||
| Prospective monitoring of lipid profiles in children receiving pravastatin preemptively after renal transplantation | Q46269334 | ||
| Accelerated atherosclerosis in systemic lupus erythematosus: implications for patient management | Q57219130 | ||
| Prevalence and relation to risk factors of carotid atherosclerosis and left ventricular hypertrophy in systemic lupus erythematosus and antiphospholipid antibody syndrome | Q57219336 | ||
| Pravastatin Therapy and the Risk of Stroke | Q57274395 | ||
| Risk factors for coronary artery disease in patients with systemic lupus erythematosus | Q67586359 | ||
| Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease | Q71875783 | ||
| Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone | Q72003544 | ||
| Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study | Q73106702 | ||
| Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus | Q73167867 | ||
| Statins as a newly recognized type of immunomodulator | Q73252634 | ||
| Risks and benefits of statins in lupus erythematosus | Q75244662 | ||
| P433 | issue | 11 | |
| P921 | main subject | systemic lupus erythematosus | Q1485 |
| P304 | page(s) | 1071-1077 | |
| P577 | publication date | 2007-04-03 | |
| P1433 | published in | Rheumatology International | Q15763689 |
| P1476 | title | A pravastatin dose-escalation study in systemic lupus erythematosus | |
| P478 | volume | 27 |
| Q87858477 | Atorvastatin effect on systemic lupus erythematosus disease activity: a double-blind randomized clinical trial |
| Q39123611 | Dyslipidemia in systemic lupus erythematosus |
| Q50214328 | Immune modulatory effects of statins. |
| Q52592135 | Lipid Testing and Statin Prescription among Medicaid Recipients with Systemic Lupus Erythematosus, Diabetes Mellitus and the General Medicaid Population. |
| Q33730536 | Management of cardiovascular complications in systemic lupus erythematosus |
| Q38230699 | Pathogenesis and treatment of atherosclerosis in lupus |
| Q46412003 | Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus |
| Q35770834 | Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS |
| Q35835877 | Statin therapy in lupus-mediated atherogenesis: two birds with one stone? |
| Q38097749 | Statins and autoimmunity |
| Q36088110 | Statins as anti-inflammatory agents in atherogenesis: molecular mechanisms and lessons from the recent clinical trials. |
| Q36059492 | The role of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (statins) in modern rheumatology |
| Q37230796 | Therapeutic manipulation of glucocorticoid metabolism in cardiovascular disease |
| Q46108350 | Treatment of dyslipidemia in idiopathic inflammatory myositis: results of the International Myositis Assessment and Clinical Studies Group survey |
| Q34027495 | Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis |
| Q33818710 | Use of atorvastatin in systemic lupus erythematosus in children and adolescents |
Search more.